- Home
- WIT vs INCY Comparison
WIT vs INCY Comparison
Compare WIT & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WIT | INCY |
|---|---|---|
| Founded | 1945 | 1991 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0B | 17.0B |
| IPO Year | 2000 | 1994 |
Fundamental Metrics
Financial Performance| Metric | WIT | INCY |
|---|---|---|
| Price | $1.75 | $117.14 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 7 | 28 |
| Target Price | $1.75 | ★ $127.74 |
| AVG Volume (30 Days) | ★ 7.3M | 1.2M |
| Earning Date | 10-15-2026 | 10-27-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | N/A | ★ 1.47 |
| Revenue | N/A | ★ $3,394,635,000.00 |
| Revenue This Year | $6.64 | $15.59 |
| Revenue Next Year | $3.02 | $5.43 |
| P/E Ratio | ★ $16.59 | $84.25 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $1.59 | $82.82 |
| 52 Week High | $3.09 | $132.60 |
Technical Indicators
Market Signals| Indicator | WIT | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 58.31 | 42.34 |
| Support Level | $1.78 | $120.79 |
| Resistance Level | $1.93 | $130.53 |
| Average True Range (ATR) | 0.04 | 3.07 |
| MACD | 0.01 | -0.59 |
| Stochastic Oscillator | 88.46 | 9.71 |
Price Performance
Historical ComparisonAbout WIT Wipro Limited
Wipro is a multinational IT services provider based in Bengaluru, India. The company pivoted into the IT space in the 1980s and grew into one of the largest Indian IT consulting companies during the dot-com boom. Nowadays, Wipro leverages its offshore outsourcing model to derive a significant portion of its revenue from North America and Europe.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.